Table 3.
Characteristics of Liver Disease in the 186 Patients Who Were HCV-RNA Positive
| Characteristic | N = 186 |
|---|---|
| Anti-HCV Therapy, n (%)a | |
| Never | 121 (65.1) |
| Ongoingb | 41 (22.0) |
| In the past | 34 (18.3) |
| Null response or partial response | 26 (76.5) |
| Relapse | 1 (2.9) |
| Abandonment or interruption due to adverse events | 5 (14.7) |
| Sustained viral response | 2 (5.9) |
| HCV Genotype, n (%) | |
| Unknown | 10 (5.4) |
| Known | 176 (94.6) |
| 1a | 82 (46.6) |
| 4 | 39 (22.2) |
| 1b | 24 (13.6) |
| 3 | 28 (15.9) |
| 2 | 3 (1.7) |
| Mixed | 0 |
| TE Results | |
| Patients with TE, n (%) | 150 (80.6) |
| Months from TE to study date, median (IQR) | 10.0 (5.6–21.9) |
| TE value–kPa, median (IQR) | 6.6 (5.4–9.1) |
| TE distribution according to cutoff values–kPa, n (%) | |
| <7.1 | 87 (58.0) |
| 7.1–9.5 | 28 (18.7) |
| 9.6–12.5 | 11 (7.3) |
| >12.5 | 24 (16.0) |
| FIB-4 Index Results | |
| Patients with FIB-4, n (%) | 185 (99.5) |
| FIB-4 value, median (IQR) | 1.5 (1.1–2.2) |
| FIB-4 Distribution According to Cutoff Values, n (%) | |
| ≤1 | 39 (21.1) |
| 1–3.25 | 122 (65.9) |
| ≥3.25 | 24 (13.0) |
Abbreviations: DAA, direct-acting antiviral agent; FIB-4, fibrosis 4; HCV, hepatitis C virus; IQR, interquartile range; RNA, ribonucleic acid; TE, transient elastography.
a
The number of patients in the “never”, “ongoing”, and “in the past” categories total more than 186 because the groups overlap. Of the 186 patients, 121 were naive for anti-HCV therapy, 31 are currently receiving therapy but had not received it previously, 24 are not currently receiving therapy but had received it in the past, and 10 are currently receiving treatment and received it in the past.
b
All 41 patients in this category were receiving oral DAA therapy during the study.